Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra, Inc. (NYSE: PEN) reported Q2 2024 financial results with revenue of $299.4 million, up 14.5% year-over-year. U.S. thrombectomy revenue increased 24.9% to $153.7 million. The company reported a loss from operations of $81.0 million, including $110.3 million in one-time non-cash impairment charges. Excluding these charges, non-GAAP income from operations was $31.7 million.
Penumbra updated its 2024 revenue guidance to $1,180-$1,200 million, a $60 million reduction at the midpoint. This change reflects challenges in China, delays in European product launches, strategic changes in Immersive Healthcare, and adjusted U.S. thrombectomy growth expectations. The company maintains its outlook for non-GAAP gross margin and operating margin expansion.
Penumbra has scheduled its Q2 2024 earnings release and conference call for July 30, 2024, at 4:30 PM ET. The company will issue a press release with financial results after the market closes on that day. Investors can join the earnings call by dialing (888) 596-4144 with the conference ID 5872954 or access the webcast via Penumbra's website under the 'Investors' tab. The webcast will remain available for at least two weeks post-call.
Penumbra announced its participation in the Truist Securities MedTech Conference on June 18, 2024. The presentation will be at 10:05am ET/7:05am PT. Investors can access the webcast through the company’s website under the 'Events and Presentations' section. The webcast will be available for two weeks post-event.
Penumbra announced that its management team will present at the William Blair Growth Stock Conference on June 6, 2024, at 12:20pm ET/9:20am PT.
The event will be webcast live and accessible through the company's website under the 'Investors' tab, where it will remain available for two weeks after the presentation.
Penumbra, Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $278.7 million, a 15.4% increase over the previous year. The company's U.S. thrombectomy revenue saw a significant growth of 35.2%. The non-GAAP income from operations was $19.3 million, and adjusted EBITDA was $37.6 million with a margin of 13.5%. Penumbra's total revenue growth and U.S. thrombectomy revenue guidance for the full year 2024 are 16-20% and 27-30%, respectively. The company expects continued growth in revenue and gross margin expansion for the year.
Penumbra, Inc. (NYSE: PEN) will be presenting at the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The webcast of the presentation will be available on the company's website for two weeks after the event.
Summary not available.
Summary not available.
Summary not available.
Summary not available.